You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective,Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage
SBC: NEUROP, INC. Topic: 102Abstract Subarachnoid hemorrhageSAHremains a serious source of neurological morbiditywith approximatelycases reported in the US each yearDespite advances in treating the initial and subsequent bleedspost surgical clipping of the aneurysm is associated with a significant risk of delayed cerebral ischemiaDCIThese events typically occur within the firstdays after aneurysmal rupture and DCI remains th ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Long-Acting G-CSF Analog for Treating ARS
SBC: BOLDER BIOTECHNOLOGY INC Topic: NIAIDDESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Advanced therapeutic for Parkinson's Disease
SBC: Inhibikase Therapeutics, Inc. Topic: 105Parkinson s DiseasePDis a progressive neurodegenerative disorder that affectsmillion patient in the U Sannually andtomillion people worldwidePD is characterized by disorders of movementwhich are caused by the progressive loss of dopamine neurons in the substantia nigra pars compactaSNpcand autonomic dysfunctionanxietydepressionsleep disorders and cognitive impairment that are due to the degenerati ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Low Cost Multi-pathogen Laser Diagnostic for HIV and AIDS Co-Infections
SBC: Precision Photonics Corporation Topic: N/ADESCRIPTION (provided by applicant): Diagnosis and medical management of HIV-infected individuals is significantly enhanced if one can simultaneously define the subset of the most common co-infections for which patients are at risk. Unfortunately, running such a series of parallel diagnostic tests is cost prohibitive, particularly in low-resource settings. Precision Photonics Corporation proposes ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Long-Acting G-CSF Analog for Treating ARS
SBC: BOLDER BIOTECHNOLOGY INC Topic: NIAIDDESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Clinical Development of Combination Plague/Smallpox Vaccine
SBC: INVIRAGEN, LLC Topic: N/ADESCRIPTION (provided by applicant): The threat of terrorist attacks using biological weapons continues to be a major national security issue. A new congressional report (www.preventwmd.gov, Dec 3, 2008) indicates that a terrorist attack with bioweapons or other weapons of mass destruction might occur before 2013. Plague and smallpox could be devastating bioweapons if intentionally released. A rel ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Economic Spectroscopic Evaluation of Cervical Cancer
SBC: GUIDED THERAPEUTICS Topic: N/ADESCRIPTION (provided by applicant): Guided Therapeutics has developed the LightTouch(R), a non invasive, point of care device that uses a combination of fluorescence and reflectance spectroscopy to measure the entire ecto-cervix in an imaging format. Our test is intended for use prior to colposcopy by a trained healthcare professional (e.g., physician, nurse practitioner, physician's assistant) t ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
An Automated Platform for High-throughput Network Electrophysiology
SBC: Axion Biosystems, Inc. Topic: 102DESCRIPTION provided by applicant In response to the program announcement for Phase IIb proposals for complex in vitro brain and behavior tools PA this proposed study automates all aspects of in vitro Microelectrode Array MEA technology to deliver the first ever high throughput MEA based screening system This development will not only enable rapid advancements in the study of basi ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II
SBC: MBC Pharma, Inc. Topic: NCIProject Summary AbstractThe overall aim of this project is to further develop a novel gemcitabine ibandronate conjugate alone and or as part of a combination therapy for the treatment of osteosarcoma and associated metastasesThe conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone homing bisphosphonate IbandronateThe novel conjugate directly addresses the limi ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
An Automated Platform for High-throughput Network Electrophysiology
SBC: Axion Biosystems, Inc. Topic: NINDSDESCRIPTION (provided by applicant): In response to the program announcement for Phase IIb proposals for complex, in-vitro brain and behavior tools (PA-11-135), this proposed study automates all aspects of in-vitro Microelectrode Array (MEA) technology todeliver the first ever high throughput MEA-based screening system. This development will not only enable rapid advancements in the study of basic ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health